ARDELYX, INC.
tenapanor
irritable bowel syndrome with constipation (IBS-C)
Countdown
1273days
Phase 3 readout · ~ Dec 31, 2029 estimated
What's at stake
Phase 3 trial results for tenapanor in irritable bowel syndrome with constipation (IBS-C) are due ~ Dec 31, 2029. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“the year in which IBSRELA will achieve annual U.S. net product sales revenue of $1 billion;”